Ratings Rayence Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
8,380 ^KRW	0.00%		-1.18%	-10.37%

Mar. 18	Rayence Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Rayence Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2023	CI

The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
RAYENCE CO., LTD.	-10.37%	96.74M		-
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.	-6.90%	14.43B		-
IRAY TECHNOLOGY COMPANY LIMITED	-40.72%	2.77B		C-
SONOSCAPE MEDICAL CORP.	-15.01%	2.44B		-
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.	-14.64%	1.41B	-	-
CORETAG, INC.	-.--%	1.12B	-	-
NANO-X IMAGING LTD.	+38.46%	521M		-
GUERBET	+88.46%	494M		B+
DETECTION TECHNOLOGY OYJ	+24.09%	277M		C
DRTECH CORPORATION	-11.15%	213M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality